Cinacalcet and Acute Heart Failure on Dialysis - A New Association

Abstract

Secondary hyperparathyroidism (SHPT) is common in end stage renal disease and is associated with abnormal bone and mineral metabolism, vascular calcification, bone fracture and increased cardiovascular risk. Cinacalcet is an increasingly widely-used calcimimetic agent for the control of SHPT in such patients and trial data has confirmed its use as an efficacious strategy in achieving target parathyroid hormone (PTH) targets. Here we describe a previously undocumented side-effect of cinacalcet treatment in a man on haemodialysis who developed a new and severe dilated cardiomyopathy in clear association with starting cinacalcet. This subsequently resolved fully after withdrawal of the drug. This case, we believe, is the first documented case of severe left ventricular systolic dysfunction temporally associated with cinacalcet use.




J Med Cases. 2013;4(6):389-392
doi: https://doi.org/10.4021/jmc1029w